Spore Briefing Weekly: 2026-10-26 – 2026-11-01

Spore Briefing Weekly: 2026-10-26 – 2026-11-01

TLDR

  • Psychedelic-assisted therapy shows early promise for PTSD and depression, but evidence is still developing.
  • No consistent link found between psychedelic use and psychosis in the general population.
  • Fungal nutraceuticals may alter gut microbiome function in colorectal cancer patients.
  • Astragalus compounds may influence Alzheimer’s disease pathways, but human trials are lacking.
  • Be cautious of overhyped claims about psychedelics in autism and other unproven uses.

1. Biggest Study of the Week: Psychedelic-Assisted Psychotherapy (2020–2025)

A 2026 scoping review in Frontiers in Psychology link examined the clinical evidence, mechanisms, safety, and ethics of psychedelic-assisted psychotherapy (PAT) from 2020 to 2025. The strongest evidence comes from MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for depression, with randomized trials showing symptom reduction in both cases. DMT-assisted therapy, however, remains in early stages. Most of the data comes from trial registrations or industry reports, not peer-reviewed studies. The evidence grade is B, and the review calls for standardized research and a better understanding of the therapeutic context.


2. Most Overhyped Headline: Psychedelics for Autism Spectrum Disorder

A narrative review in Europe PMC link suggests that psychedelics like psilocybin and LSD might help with social anxiety and emotional dysregulation in autism. But the evidence is weak — limited to preclinical studies and indirect clinical observations. The review doesn’t support use for core symptoms like social communication deficits. The evidence grade is D, and the risk grade is high. This is a clear example of overhype. The science isn’t there yet.


3. Functional Mushroom Watch: Fungal Nutraceuticals in Colorectal Cancer

A randomized, double-blind, placebo-controlled trial in Europe PMC link found that Micodigest®, a fungal nutraceutical, may change the gut microbiome in colorectal cancer patients. The study saw increases in CRISPR-associated systems and chitin-derived carbohydrate utilization. But there’s no direct evidence of clinical benefit. The evidence grade is B, and the sample size was small (n=37). This is exploratory work, not a confirmed treatment.


4. Psychedelic Research Watch: Psychedelics and Psychosis

A systematic review in Journal of Psychopharmacology link found no consistent link between lifetime psychedelic use and psychosis in population-based studies. In controlled clinical settings, the risk was low. Emergency and toxicological data showed higher rates of psychotic symptoms, but those cases likely involved people already at higher risk — those with personal or family psychiatric history. The evidence grade is A, but causality can’t be established.


5. Clinical Trial Watch: PROMETHEUS Study on Healthy Aging

The PROMETHEUS trial, published in Europe PMC link, is a feasibility study of a multimodal, personalized intervention for healthy aging. It involves 20 participants and combines lifestyle, nutraceuticals, and gerotype-based interventions. The study will assess muscle strength, immune function, and cognitive performance. The evidence grade is B due to small sample size and short duration. This is exploratory, not a confirmed strategy for aging.


6. DMT / Consciousness Watch: Astragalus and Alzheimer’s Disease

A systematic review in Europe PMC link found that Astragalus-derived phytochemicals may influence multiple signaling pathways in Alzheimer’s disease, including PI3K/Akt, Nrf2/ARE, and NF-κB. These could reduce oxidative stress and neuroinflammation. But the evidence is preclinical. The evidence grade is A, but human trials are limited. More research is needed before any conclusions can be drawn.


7. Don’t Get Scammed: Natural Products and Exercise-Induced Fatigue

A systematic review in Europe PMC link suggests that natural products may alleviate exercise-induced fatigue by modulating the gut microbiome, specifically through SCFA-AMPK/PGC-1α pathways. However, the evidence is based on animal studies and one human trial. The risk grade is high. This is not a confirmed treatment. Caution is needed when interpreting these results.


Best Content Opportunities

  1. \”Psychedelics for PTSD: What the Evidence Actually Says\” – A short explainer on the current state of clinical trials for MDMA and psilocybin.
  2. \”Are Psychedelics Safe for the General Public? A Look at the Evidence\” – A deep dive into the Journal of Psychopharmacology review on psychosis and psychedelic use.
  3. \”Functional Mushrooms in Cancer Care: What’s the Real Story?\” – A video unpacking the Europe PMC study on Micodigest® and gut microbiome changes in CRC patients.
  4. \”The Overhyped Autism and Psychedelics Narrative\” – A critical take on the Europe PMC review and the need for more rigorous research.

Sources


Final Takeaway

This week’s research highlights both exciting developments and important limitations in the psychedelic and functional mushroom spaces. While MDMA and psilocybin show promise for PTSD and depression, the evidence is still emerging, and context and supervision matter. The lack of consistent evidence linking psychedelics to psychosis in the general population is reassuring, but caution is needed when interpreting early findings. Functional mushrooms may alter gut microbiome function in colorectal cancer patients, but clinical benefits remain unproven. And while Astragalus compounds may influence Alzheimer’s pathways, human trials are lacking. As always, stay skeptical, follow the science, and avoid overhyped claims.

Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

Frequently asked questions

Are psychedelics safe for the general public?
Research suggests no consistent link between psychedelic use and psychosis in the general population, but more studies are needed to fully understand long-term safety. Always consult a qualified professional before considering any substance use.
Can psychedelics help with PTSD or depression?
Early evidence from clinical trials shows promise for MDMA-assisted therapy in PTSD and psilocybin-assisted therapy in depression, but the evidence is still developing and requires further standardized research.
Do functional mushrooms help in cancer treatment?
Some studies suggest fungal nutraceuticals may alter gut microbiome function in colorectal cancer patients, but there is no direct evidence of clinical benefit, and more research is needed.
Is there any evidence that psychedelics help with autism?
Current evidence is limited to preclinical studies and indirect observations, and there is no support for use in core symptoms of autism. More rigorous research is needed before any conclusions can be drawn.
Can natural products help with exercise-induced fatigue?
Some studies suggest natural products may influence pathways related to exercise-induced fatigue, but the evidence is based on animal studies and limited human trials, and more research is needed.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *